The poster will feature key preclinical data demonstrating the mode-of-action of ImmunOs Therapeutics´ lead program iosH2. The compound is a first-in-class multi-functional agent that promotes key components of the innate immune system and synergizes with the adaptive immune system, thereby leading to profound anti-tumor activity. A Phase I trial is currently in preparation.
Presentation Details
Poster Title: "iosH2 exerts potent anti-tumor activity by blocking LILRB1/2 and KIR3DL1 receptor signaling"
Abstract ID: 865
Category: Novel Single-Agent Immunotherapies
Date: Friday, Nov. 12, 2021
Time: 7:00 am – 5:00 pm
Location: Poster Hall at the Walter E. Washington Convention Center
Accepted abstracts can be found in the Journal for ImmunoTherapy of Cancer (JITC).
In addition, ImmunOs´ Therapeutics COO & CBO Jeffrey Abbey will attend this year´s virtual BIO-Europe 2021 and will be available for one-on-one meetings.
ImmunOs Therapeutics AG focuses on the development of a new class of biologic therapeutics for the treatment of cancer and autoimmune diseases. The Company has established a proprietary R&D platform for the development of HLA-based therapeutics addressing multiple targets via a single fusion protein. Its novel compounds are fully human and modulate the innate immune system, synergizing with the adaptive immune system. ImmunOs Therapeutics‘ lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.
ImmunOs Therapeutics AG is supported by top-tier investors including Pfizer Ventures, BioMed Partners, Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd and UZH Life Sciences Fund as well as undisclosed private investors.
The Company is a spin-off from the Universities of Zurich and Basel and based in Schlieren, Switzerland.
For more information, please visit www.immunostherapeutics.com
ImmunOs Therapeutics AG
WAGISTRASSE 14
CH8952 SCHLIEREN
Telefon: +41 (44) 7319035
http://www.immunostherapeutics.com/
akampion
Telefon: +49 (30) 236327-68
E-Mail: info@akampion.com
